Synaf­fix ex­pands In­novent deal; Re­ci­pharm co-de­vel­ops in­halers; Vit­riVax gets $5M for vac­cine tech

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Lon­za-owned Synaf­fix boost­ed its li­cens­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER